-transparent.png){kind=logo}
The mode of action of mizoribine (MZR) as a B cell inhibitor was studied using DBA/2 mice. Its in vitro administration significantly delayed the primary response in hemagglutinin production against sheep erythrocytes by suppressing the IgM antibody formation. In vitro plaque-forming cell (PFC) response against both T-dependent and T-independent antigens, such as TNP-SRBC and TNP-Brucella abortus, was dose-dependently suppressed by MZR. Since PFC formation by the T-depleted fraction of splenocytes was likewise suppressed, MZR may inhibit humoral antibody response by directly affecting the B cells (and/or macrophages) as well as by modulating the regulatory T cells. MZR may only act on a certain stage of the cell cycle of B lymphocytes following antigenic stimulation. It may not interfere with the initial antigen recognition or with mature B cells.
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
April 1987,
Nihon Jinzo Gakkai shi,
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
January 1988,
International archives of allergy and applied immunology,
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
September 2004,
The Journal of antibiotics,
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
June 1971,
Immunology,
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
June 1980,
Chemico-biological interactions,
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
September 1987,
Neuropharmacology,
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
August 1973,
Archives internationales de pharmacodynamie et de therapie,
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
January 1971,
Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology,
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
June 1985,
Infection and immunity,
M Okubo, and
X M Chen, and
K Kamata, and
Y Masaki, and
T Uchiyama
January 1969,
Folia biologica,
